Results of this study focus on a direct link between hyperglycemia and the pro-inflammatory cytokines/growth factors involved in cancer survival and cardiotoxicity during the CTLA4 blocking agent ipilimumab; these effects are reversible by shifting from high glucose to low glucose or through concomitant treatment with an anti SGLT-2 drug (empagliflozin). The gene discussed is SLC5A2; the disease is Hyperglycemia.